芬兰人群富集的SLC26A7变异与先天性甲状腺功能减退症:临床谱、甲状腺组织病理与表达分析
研究在139例临床先天性甲状腺功能减退症(CH)队列中通过外显子测序鉴定SLC26A7变异,并在FinnGen数据库筛查疾病关联,分析6例人类甲状腺样本及多种小鼠模型的甲状腺组织学与特异性基因表达。发现4个新家系中4例CH患者携带纯合SLC26A7(c.1893delT, p.F631Lfs*8)致病变异,表型从严重CH伴大先天性甲状腺肿到迟发性甲减及颌面异常不等;SLC26A7在甲状腺细胞基底外侧膜定位,其表达模式依赖促甲状腺激素、GNAS活性及膳食碘水平。
要点
- SLC26A7纯合变异可导致严重CH伴大甲状腺肿,需出生时甲状腺切除。
- 携带者常见颌面异常,包括釉质发育不全、颌前突/后缩及错颌畸形。
- SLC26A7定位基底外侧膜,表达受TSH、GNAS及碘摄入调控。
核心结论
- SLC26A7致病变异相关表型谱广泛,从严重CH伴大先天性甲状腺肿到迟发性甲减及颌面异常。
- SLC26A7呈促甲状腺激素、GNAS及膳食碘依赖的基底外侧膜定位,可能解释表型变异。
研究设计与样本
- 从139例临床CH队列中通过外显子测序鉴定SLC26A7变异,并筛查FinnGen数据库(R12版)疾病关联。
- 分析6例人类甲状腺样本(含2例纯合SLC26A7致病变异携带者、甲状腺肿及甲状腺功能亢进患者、正常对照)及多种小鼠模型甲状腺。
主要发现
- 4个新家系中4例CH患者携带纯合SLC26A7(c.1893delT, p.F631Lfs*8)致病变异,其中2例因大甲状腺肿压迫气管出生时即需甲状腺切除。
- 1例纯合携带者CH筛查正常但16岁发生甲减,1例杂合携带者出生时患永久性CH。
- 颌面异常常见:4例携带者釉质发育不全,8/24例携带者需正畸治疗的颌前突/后缩及错颌畸形。
- 纯合患者甲状腺组织学标志为甲状腺细胞肥大伴大胶质聚集体。
- FinnGen筛查显示该变异在芬兰人群富集75倍,另发现少数纯合及7例杂合早发甲减伴颌面异常病例。
关键数值与推荐
- 纯合SLC26A7(c.1893delT, p.F631Lfs*8)致病变异在FinnGen中芬兰人群富集75倍。
- 8/24例携带者需正畸治疗的颌面异常(颌前突/后缩及错颌畸形)。
临床怎么用
- 对先天性甲状腺功能减退症伴大甲状腺肿或颌面异常者,可考虑SLC26A7基因检测。
- 携带SLC26A7致病变异者需监测甲状腺功能,迟发甲减可在16岁出现。
局限性
- 人类甲状腺样本量小(共6例,含2例纯合携带者),组织学发现需扩大验证。
- SLC26A7表达调控机制主要基于小鼠模型,向人类外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Defects in thyroid hormone synthesis at birth lead to congenital hypothyroidism (CH). Recently, pathogenic variants in the SLC26A7 gene have been linked to dyshormonogenetic goitrous CH. This anion transporter is highly expressed in the thyroid and is involved in thyroid hormone synthesis; however, its exact function and cellular localization remain unclear. In this study, we investigated SLC26A7 variants in Finnish patients with CH, characterized the phenotypes, and analyzed thyroid-specific gene expression. METHODS: SLC26A7 variants were identified from a clinical CH cohort (n = 139) using exome sequencing, and the FinnGen database (R12 release) was screened for disease associations. Thyroid histology and thyroid-specific gene expression were analyzed in six human samples (including two homozygous SLC26A7 pathogenic variant carriers, patients with goitrous and hyperactive thyroids, and normal controls) and in thyroids from different mouse models (including hypo- and hyperthyroid mice, thyroid-specific G-protein deficient, and Slc26a7-knockout mice). RESULTS: Four CH patients from four novel families carried the homozygous SLC26A7 (c.1893delT, p.F631Lfs*8) pathogenic variant. Two had large trachea-compressing goiters, requiring thyroidectomy already at birth. In addition, one homozygous participant with normal CH screening results developed hypothyroidism at age 16, and one patient with heterozygous SLC26A7 pathogenic variant had permanent CH at birth. Dentofacial abnormalities were frequently noted, including enamel hypoplasia (in four carriers), pro- or retrognathia, and malocclusion requiring orthodontic treatment (in 8/24 carriers). Thyrocyte hypertrophy with large colloid aggregates was a hallmark of homozygous patients. FinnGen screening revealed a 75-fold enrichment of the variant in the Finnish population, identifying a few other homozygous and seven heterozygous cases with early-onset hypothyroidism and dentofacial abnormalities. In human thyrocytes, SLC26A7 was localized to the basolateral membrane, with intense staining in hyperthyroid samples, while in mouse thyroid models, its expression pattern depended on dietary iodide levels, thyrotropin signaling, and GNAS activity. CONCLUSIONS: We describe variable phenotypes associated with the SLC26A7 pathogenic variant, ranging from severe CH with large congenital goiters to delayed onset hypothyroidism and dentofacial abnormalities. SLC26A7 shows thyrotropin-, GNAS-, and dietary iodine-dependent basolateral localization, suggesting their role in phenotypic variations.
引用
- Niuro L, Ojala J, Ravi R, et al. Finnish-Enriched SLC26A7 Variant in Congenital Hypothyroidism: Clinical Spectrum, Thyroid Histopathology, and Expression Analysis. Thyroid. 2026. PMID: 41791885. doi:10.1177/10507256251411983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。